Cargando…

Molecular Mechanism Operating in Animal Models of Neurogenic Detrusor Overactivity: A Systematic Review Focusing on Bladder Dysfunction of Neurogenic Origin

Neurogenic detrusor overactivity (NDO) is a severe lower urinary tract disorder, characterized by urinary urgency, retention, and incontinence, as a result of a neurologic lesion that results in damage in neuronal pathways controlling micturition. The purpose of this review is to provide a comprehen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreira, Ana, Nascimento, Diogo, Cruz, Célia Duarte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959149/ https://www.ncbi.nlm.nih.gov/pubmed/36834694 http://dx.doi.org/10.3390/ijms24043273

Ejemplares similares

Botulinum Toxin in Neurogenic Detrusor Overactivity
por: D'Ancona, Carlos Arturo Levi, et al.
Publicado: (2012)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

Nerve sprouting and neurogenic inflammation characterize the neurogenic detrusor overactive bladder of patients no longer responsive to drug therapies
por: Traini, Chiara, et al.
Publicado: (2019)

OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children
por: Austin, Paul F., et al.
Publicado: (2020)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

Adaptive changes of telocytes in the urinary bladder of patients affected by neurogenic detrusor overactivity
por: Traini, Chiara, et al.
Publicado: (2017)

Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder
por: Kaga, Kanya, et al.
Publicado: (2020)

The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin
por: Traini, Chiara, et al.
Publicado: (2019)

Inosine Improves Neurogenic Detrusor Overactivity following Spinal Cord Injury
por: Chung, Yeun Goo, et al.
Publicado: (2015)

Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity
por: Cho, Young Sam, et al.
Publicado: (2016)

Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
por: Hui, C, et al.
Publicado: (2016)

Sphingosine Kinase 1 urothelial expression is increased in patients with neurogenic detrusor overactivity
por: Ballouhey, Quentin, et al.
Publicado: (2015)

OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review
por: Zhang, Rui, et al.
Publicado: (2015)

Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
por: Sano, Yamato, et al.
Publicado: (2023)

Characterization of upper lamina propria interstitial cells in bladders from patients with neurogenic detrusor overactivity and bladder pain syndrome
por: Gevaert, Thomas, et al.
Publicado: (2011)

AB206. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
por: Chen, Hui, et al.
Publicado: (2016)

Development of Neurogenic Detrusor Overactivity after Thoracic Spinal Cord Injury Is Accompanied by Time-Dependent Changes in Lumbosacral Expression of Axonal Growth Regulators
por: Chambel, Sílvia Sousa, et al.
Publicado: (2022)

Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis
por: Wu, Shang-Jun, et al.
Publicado: (2019)

Detrusor Arreflexia as an End Stage of Neurogenic Bladder in HAM/TSP?
por: Tannus, Matheus, et al.
Publicado: (2011)

Efficacy and Safety of OnabotulinumtoxinA in Treating Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis
por: Zhou, Xin, et al.
Publicado: (2015)

Real-World Effects of Mirabegron in Patients with Chronic Neurogenic Detrusor Overactivity – A Retrospective Cohort Study
por: Krebs, Jörg, et al.
Publicado: (2020)

Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity
por: Averbeck, Marcio Augusto
Publicado: (2022)

Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
por: Rohrsted, Malene, et al.
Publicado: (2012)

Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model
por: Biardeau, Xavier, et al.
Publicado: (2017)

Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury
por: Lombardi, Giuseppe, et al.
Publicado: (2017)

Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis
por: Yuan, Hejia, et al.
Publicado: (2017)

BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study
por: Maignel, Jacquie, et al.
Publicado: (2022)

Herpes zoster-induced urologic and gastrointestinal dysfunction with residual neurogenic detrusor underactivity
por: Biglione, Bianca, et al.
Publicado: (2022)

A Korean Postmarketing Study Assessing the Effectiveness of OnabotulinumtoxinA for the Treatment of Neurogenic Detrusor Overactivity or Idiopathic Overactive Bladder Using a Validated Patient-Reported Outcome Measure
por: Ko, Kwang Jin, et al.
Publicado: (2019)

Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data
por: Andretta, Elena, et al.
Publicado: (2022)

Semiconditional Electrical Stimulation of Pudendal Nerve Afferents Stimulation to Manage Neurogenic Detrusor Overactivity in Patients with Spinal Cord Injury
por: Lee, Young-Hee, et al.
Publicado: (2011)

Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
por: Tarcan, Tufan, et al.
Publicado: (2014)

Neurogenic Detrusor Overactivity Is Associated with Decreased Expression and Function of the Large Conductance Voltage- and Ca(2+)-Activated K(+) Channels
por: Hristov, Kiril L., et al.
Publicado: (2013)

Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity
por: Leitner, Lorenz, et al.
Publicado: (2016)

Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study
por: Baka‐Ostrowska, Małgorzata, et al.
Publicado: (2021)

Percutaneous tibial nerve stimulation in the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: a historically controlled study
por: Carilli, Marco, et al.
Publicado: (2023)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
por: Al-Ghazo, Mohammed A., et al.
Publicado: (2011)

Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan—A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study)
por: Wang, Chung-Cheng, et al.
Publicado: (2021)

Neurogenic Bladder
por: Dorsher, Peter T., et al.
Publicado: (2012)

Contractile and Structural Properties of Detrusor from Children with Neurogenic Lower Urinary Tract Dysfunction
por: Johal, Navroop, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lf7sj3bu7pf17npcv6b6la6t6e